ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Pediatric Diabetes Therapeutic Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-28N17035
Home | Market Reports | Health| Health Conditions| Endocrine Conditions
Global Pediatric Diabetes Therapeutic Market Research Report 2024
BUY CHAPTERS

Global Pediatric Diabetes Therapeutic Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-28N17035
Report
October 2025
Pages:131
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Sanofi
Vertex Pharmaceuticals Incorporated
Novo Nordisk A S
Astrazeneca plc
MannKind Corporation
Xeris Pharmaceuticals
Amphastar Pharmaceuticals Inc

Pediatric Diabetes Therapeutic Market

The global Pediatric Diabetes Therapeutic market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Pediatric diabetes therapeutic options aim to manage blood glucose levels in children and adolescents diagnosed with diabetes mellitus. The two main types of pediatric diabetes are type 1 diabetes (T1D) and type 2 diabetes (T2D), with T1D being more common in children.
From a downstream perspective, Hospitals accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Pediatric Diabetes Therapeutic leading manufacturers including Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Vertex Pharmaceuticals incorporated, Novo Nordisk A/S, AstraZeneca, MannKind Corporation, Xeris Pharmaceuticals, Amphastar Pharmaceuticals, Inc., etc., dominate supply; the top five capture approximately % of global revenue, with Boehringer Ingelheim International GmbH leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Pediatric Diabetes Therapeutic market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Pediatric Diabetes Therapeutic Market Report

Report Metric Details
Report Name Pediatric Diabetes Therapeutic Market
Segment by Type
  • Type 1
  • Type 2
Segment by Application
  • Hospitals
  • Specialty Clinics
  • Others
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Vertex Pharmaceuticals incorporated, Novo Nordisk A/S, AstraZeneca, MannKind Corporation, Xeris Pharmaceuticals, Amphastar Pharmaceuticals, Inc.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Pediatric Diabetes Therapeutic study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Pediatric Diabetes Therapeutic Market report?

Ans: The main players in the Pediatric Diabetes Therapeutic Market are Boehringer Ingelheim International GmbH, Eli Lilly and Company, Sanofi, Vertex Pharmaceuticals incorporated, Novo Nordisk A/S, AstraZeneca, MannKind Corporation, Xeris Pharmaceuticals, Amphastar Pharmaceuticals, Inc.

What are the Application segmentation covered in the Pediatric Diabetes Therapeutic Market report?

Ans: The Applications covered in the Pediatric Diabetes Therapeutic Market report are Hospitals, Specialty Clinics, Others

What are the Type segmentation covered in the Pediatric Diabetes Therapeutic Market report?

Ans: The Types covered in the Pediatric Diabetes Therapeutic Market report are Type 1, Type 2

1 Study Coverage
1.1 Introduction to Pediatric Diabetes Therapeutic: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Pediatric Diabetes Therapeutic Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Type 1
1.2.3 Type 2
1.3 Market Segmentation by Application
1.3.1 Global Pediatric Diabetes Therapeutic Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Pediatric Diabetes Therapeutic Revenue Estimates and Forecasts 2020-2031
2.2 Global Pediatric Diabetes Therapeutic Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Pediatric Diabetes Therapeutic Sales Estimates and Forecasts 2020-2031
2.4 Global Pediatric Diabetes Therapeutic Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Pediatric Diabetes Therapeutic Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Pediatric Diabetes Therapeutic Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Type 1 Market Size by Manufacturers
3.5.2 Type 2 Market Size by Manufacturers
3.6 Global Pediatric Diabetes Therapeutic Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Pediatric Diabetes Therapeutic Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Pediatric Diabetes Therapeutic Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Pediatric Diabetes Therapeutic Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Pediatric Diabetes Therapeutic Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Pediatric Diabetes Therapeutic Sales and Revenue by Type (2020-2031)
6.4 North America Pediatric Diabetes Therapeutic Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Pediatric Diabetes Therapeutic Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Pediatric Diabetes Therapeutic Sales and Revenue by Type (2020-2031)
7.4 Europe Pediatric Diabetes Therapeutic Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Pediatric Diabetes Therapeutic Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Pediatric Diabetes Therapeutic Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Pediatric Diabetes Therapeutic Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Pediatric Diabetes Therapeutic Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Pediatric Diabetes Therapeutic Sales and Revenue by Type (2020-2031)
9.4 Central and South America Pediatric Diabetes Therapeutic Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Pediatric Diabetes Therapeutic Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Pediatric Diabetes Therapeutic Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Pediatric Diabetes Therapeutic Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Pediatric Diabetes Therapeutic Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Boehringer Ingelheim International GmbH
11.1.1 Boehringer Ingelheim International GmbH Corporation Information
11.1.2 Boehringer Ingelheim International GmbH Business Overview
11.1.3 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.1.4 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic Sales by Product in 2024
11.1.6 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic Sales by Application in 2024
11.1.7 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic Sales by Geographic Area in 2024
11.1.8 Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic SWOT Analysis
11.1.9 Boehringer Ingelheim International GmbH Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Corporation Information
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.2.4 Eli Lilly and Company Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Eli Lilly and Company Pediatric Diabetes Therapeutic Sales by Product in 2024
11.2.6 Eli Lilly and Company Pediatric Diabetes Therapeutic Sales by Application in 2024
11.2.7 Eli Lilly and Company Pediatric Diabetes Therapeutic Sales by Geographic Area in 2024
11.2.8 Eli Lilly and Company Pediatric Diabetes Therapeutic SWOT Analysis
11.2.9 Eli Lilly and Company Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.3.4 Sanofi Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Sanofi Pediatric Diabetes Therapeutic Sales by Product in 2024
11.3.6 Sanofi Pediatric Diabetes Therapeutic Sales by Application in 2024
11.3.7 Sanofi Pediatric Diabetes Therapeutic Sales by Geographic Area in 2024
11.3.8 Sanofi Pediatric Diabetes Therapeutic SWOT Analysis
11.3.9 Sanofi Recent Developments
11.4 Vertex Pharmaceuticals incorporated
11.4.1 Vertex Pharmaceuticals incorporated Corporation Information
11.4.2 Vertex Pharmaceuticals incorporated Business Overview
11.4.3 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.4.4 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic Sales by Product in 2024
11.4.6 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic Sales by Application in 2024
11.4.7 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic Sales by Geographic Area in 2024
11.4.8 Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic SWOT Analysis
11.4.9 Vertex Pharmaceuticals incorporated Recent Developments
11.5 Novo Nordisk A/S
11.5.1 Novo Nordisk A/S Corporation Information
11.5.2 Novo Nordisk A/S Business Overview
11.5.3 Novo Nordisk A/S Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.5.4 Novo Nordisk A/S Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Novo Nordisk A/S Pediatric Diabetes Therapeutic Sales by Product in 2024
11.5.6 Novo Nordisk A/S Pediatric Diabetes Therapeutic Sales by Application in 2024
11.5.7 Novo Nordisk A/S Pediatric Diabetes Therapeutic Sales by Geographic Area in 2024
11.5.8 Novo Nordisk A/S Pediatric Diabetes Therapeutic SWOT Analysis
11.5.9 Novo Nordisk A/S Recent Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Corporation Information
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.6.4 AstraZeneca Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 AstraZeneca Recent Developments
11.7 MannKind Corporation
11.7.1 MannKind Corporation Corporation Information
11.7.2 MannKind Corporation Business Overview
11.7.3 MannKind Corporation Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.7.4 MannKind Corporation Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 MannKind Corporation Recent Developments
11.8 Xeris Pharmaceuticals
11.8.1 Xeris Pharmaceuticals Corporation Information
11.8.2 Xeris Pharmaceuticals Business Overview
11.8.3 Xeris Pharmaceuticals Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.8.4 Xeris Pharmaceuticals Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Xeris Pharmaceuticals Recent Developments
11.9 Amphastar Pharmaceuticals, Inc.
11.9.1 Amphastar Pharmaceuticals, Inc. Corporation Information
11.9.2 Amphastar Pharmaceuticals, Inc. Business Overview
11.9.3 Amphastar Pharmaceuticals, Inc. Pediatric Diabetes Therapeutic Product Models, Descriptions and Specifications
11.9.4 Amphastar Pharmaceuticals, Inc. Pediatric Diabetes Therapeutic Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Amphastar Pharmaceuticals, Inc. Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Pediatric Diabetes Therapeutic Industry Chain
12.2 Pediatric Diabetes Therapeutic Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Pediatric Diabetes Therapeutic Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Pediatric Diabetes Therapeutic Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Pediatric Diabetes Therapeutic Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Pediatric Diabetes Therapeutic Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Boehringer Ingelheim International GmbH
Eli Lilly and Company
Sanofi
Vertex Pharmaceuticals Incorporated
Novo Nordisk A S
Astrazeneca plc
MannKind Corporation
Xeris Pharmaceuticals
Amphastar Pharmaceuticals Inc
List of Tables
 Table 1. Global Pediatric Diabetes Therapeutic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Pediatric Diabetes Therapeutic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Pediatric Diabetes Therapeutic Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Pediatric Diabetes Therapeutic Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Pediatric Diabetes Therapeutic Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Pediatric Diabetes Therapeutic Sales by Region (2020-2025) & (K Units)
 Table 8. Global Pediatric Diabetes Therapeutic Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Pediatric Diabetes Therapeutic Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Pediatric Diabetes Therapeutic Sales Share by Manufacturers (2020-2025)
 Table 12. Global Pediatric Diabetes Therapeutic Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Pediatric Diabetes Therapeutic Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Pediatric Diabetes Therapeutic by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pediatric Diabetes Therapeutic as of 2024)
 Table 16. Global Pediatric Diabetes Therapeutic Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Pediatric Diabetes Therapeutic Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Pediatric Diabetes Therapeutic Manufacturing Base and Headquarters
 Table 19. Global Pediatric Diabetes Therapeutic Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Pediatric Diabetes Therapeutic Sales by Type (2020-2025) & (K Units)
 Table 23. Global Pediatric Diabetes Therapeutic Sales by Type (2026-2031) & (K Units)
 Table 24. Global Pediatric Diabetes Therapeutic Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Pediatric Diabetes Therapeutic Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Pediatric Diabetes Therapeutic ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Pediatric Diabetes Therapeutic Sales by Application (2020-2025) & (K Units)
 Table 29. Global Pediatric Diabetes Therapeutic Sales by Application (2026-2031) & (K Units)
 Table 30. Pediatric Diabetes Therapeutic High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Pediatric Diabetes Therapeutic Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Pediatric Diabetes Therapeutic Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Pediatric Diabetes Therapeutic ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Pediatric Diabetes Therapeutic Growth Accelerators and Market Barriers
 Table 37. North America Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Pediatric Diabetes Therapeutic Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Pediatric Diabetes Therapeutic Growth Accelerators and Market Barriers
 Table 40. Europe Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Pediatric Diabetes Therapeutic Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Pediatric Diabetes Therapeutic Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Pediatric Diabetes Therapeutic Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Pediatric Diabetes Therapeutic Investment Opportunities and Key Challenges
 Table 47. Central and South America Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Pediatric Diabetes Therapeutic Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Pediatric Diabetes Therapeutic Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Boehringer Ingelheim International GmbH Corporation Information
 Table 51. Boehringer Ingelheim International GmbH Description and Major Businesses
 Table 52. Boehringer Ingelheim International GmbH Product Models, Descriptions and Specifications
 Table 53. Boehringer Ingelheim International GmbH Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Boehringer Ingelheim International GmbH Sales Value Proportion by Product in 2024
 Table 55. Boehringer Ingelheim International GmbH Sales Value Proportion by Application in 2024
 Table 56. Boehringer Ingelheim International GmbH Sales Value Proportion by Geographic Area in 2024
 Table 57. Boehringer Ingelheim International GmbH Pediatric Diabetes Therapeutic SWOT Analysis
 Table 58. Boehringer Ingelheim International GmbH Recent Developments
 Table 59. Eli Lilly and Company Corporation Information
 Table 60. Eli Lilly and Company Description and Major Businesses
 Table 61. Eli Lilly and Company Product Models, Descriptions and Specifications
 Table 62. Eli Lilly and Company Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Eli Lilly and Company Sales Value Proportion by Product in 2024
 Table 64. Eli Lilly and Company Sales Value Proportion by Application in 2024
 Table 65. Eli Lilly and Company Sales Value Proportion by Geographic Area in 2024
 Table 66. Eli Lilly and Company Pediatric Diabetes Therapeutic SWOT Analysis
 Table 67. Eli Lilly and Company Recent Developments
 Table 68. Sanofi Corporation Information
 Table 69. Sanofi Description and Major Businesses
 Table 70. Sanofi Product Models, Descriptions and Specifications
 Table 71. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Sanofi Sales Value Proportion by Product in 2024
 Table 73. Sanofi Sales Value Proportion by Application in 2024
 Table 74. Sanofi Sales Value Proportion by Geographic Area in 2024
 Table 75. Sanofi Pediatric Diabetes Therapeutic SWOT Analysis
 Table 76. Sanofi Recent Developments
 Table 77. Vertex Pharmaceuticals incorporated Corporation Information
 Table 78. Vertex Pharmaceuticals incorporated Description and Major Businesses
 Table 79. Vertex Pharmaceuticals incorporated Product Models, Descriptions and Specifications
 Table 80. Vertex Pharmaceuticals incorporated Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. Vertex Pharmaceuticals incorporated Sales Value Proportion by Product in 2024
 Table 82. Vertex Pharmaceuticals incorporated Sales Value Proportion by Application in 2024
 Table 83. Vertex Pharmaceuticals incorporated Sales Value Proportion by Geographic Area in 2024
 Table 84. Vertex Pharmaceuticals incorporated Pediatric Diabetes Therapeutic SWOT Analysis
 Table 85. Vertex Pharmaceuticals incorporated Recent Developments
 Table 86. Novo Nordisk A/S Corporation Information
 Table 87. Novo Nordisk A/S Description and Major Businesses
 Table 88. Novo Nordisk A/S Product Models, Descriptions and Specifications
 Table 89. Novo Nordisk A/S Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. Novo Nordisk A/S Sales Value Proportion by Product in 2024
 Table 91. Novo Nordisk A/S Sales Value Proportion by Application in 2024
 Table 92. Novo Nordisk A/S Sales Value Proportion by Geographic Area in 2024
 Table 93. Novo Nordisk A/S Pediatric Diabetes Therapeutic SWOT Analysis
 Table 94. Novo Nordisk A/S Recent Developments
 Table 95. AstraZeneca Corporation Information
 Table 96. AstraZeneca Description and Major Businesses
 Table 97. AstraZeneca Product Models, Descriptions and Specifications
 Table 98. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. AstraZeneca Recent Developments
 Table 100. MannKind Corporation Corporation Information
 Table 101. MannKind Corporation Description and Major Businesses
 Table 102. MannKind Corporation Product Models, Descriptions and Specifications
 Table 103. MannKind Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 104. MannKind Corporation Recent Developments
 Table 105. Xeris Pharmaceuticals Corporation Information
 Table 106. Xeris Pharmaceuticals Description and Major Businesses
 Table 107. Xeris Pharmaceuticals Product Models, Descriptions and Specifications
 Table 108. Xeris Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 109. Xeris Pharmaceuticals Recent Developments
 Table 110. Amphastar Pharmaceuticals, Inc. Corporation Information
 Table 111. Amphastar Pharmaceuticals, Inc. Description and Major Businesses
 Table 112. Amphastar Pharmaceuticals, Inc. Product Models, Descriptions and Specifications
 Table 113. Amphastar Pharmaceuticals, Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 114. Amphastar Pharmaceuticals, Inc. Recent Developments
 Table 115. Key Raw Materials Distribution
 Table 116. Raw Materials Key Suppliers
 Table 117. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 118. Milestones in Production Technology Evolution
 Table 119. Distributors List
 Table 120. Market Trends and Market Evolution
 Table 121. Market Drivers and Opportunities
 Table 122. Market Challenges, Risks, and Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources


List of Figures
 Figure 1. Pediatric Diabetes Therapeutic Product Picture
 Figure 2. Global Pediatric Diabetes Therapeutic Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Type 1 Product Picture
 Figure 4. Type 2 Product Picture
 Figure 5. Global Pediatric Diabetes Therapeutic Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Hospitals
 Figure 7. Specialty Clinics
 Figure 8. Others
 Figure 9. Pediatric Diabetes Therapeutic Report Years Considered
 Figure 10. Global Pediatric Diabetes Therapeutic Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Pediatric Diabetes Therapeutic Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Pediatric Diabetes Therapeutic Revenue Market Share by Region (2020-2031)
 Figure 14. Global Pediatric Diabetes Therapeutic Sales (2020-2031) & (K Units)
 Figure 15. Global Pediatric Diabetes Therapeutic Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 16. Global Pediatric Diabetes Therapeutic Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Pediatric Diabetes Therapeutic Sales Volume Market Share in 2024
 Figure 18. Global Pediatric Diabetes Therapeutic Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. Type 1 Revenue Market Share by Manufacturer in 2024
 Figure 21. Type 2 Revenue Market Share by Manufacturer in 2024
 Figure 22. Global Pediatric Diabetes Therapeutic Sales Market Share by Type (2020-2031)
 Figure 23. Global Pediatric Diabetes Therapeutic Revenue Market Share by Type (2020-2031)
 Figure 24. Global Pediatric Diabetes Therapeutic Sales Market Share by Application (2020-2031)
 Figure 25. Global Pediatric Diabetes Therapeutic Revenue Market Share by Application (2020-2031)
 Figure 26. North America Pediatric Diabetes Therapeutic Sales YoY (2020-2031) & (K Units)
 Figure 27. North America Pediatric Diabetes Therapeutic Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Manufacturers Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) in 2024
 Figure 29. North America Pediatric Diabetes Therapeutic Sales Volume (K Units) by Type (2020- 2031)
 Figure 30. North America Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 31. North America Pediatric Diabetes Therapeutic Sales Volume (K Units) by Application (2020-2031)
 Figure 32. North America Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 33. US Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 34. Canada Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 35. Mexico Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 36. Europe Pediatric Diabetes Therapeutic Sales YoY (2020-2031) & (K Units)
 Figure 37. Europe Pediatric Diabetes Therapeutic Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Europe Top 5 Manufacturers Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) in 2024
 Figure 39. Europe Pediatric Diabetes Therapeutic Sales Volume (K Units) by Type (2020-2031)
 Figure 40. Europe Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Europe Pediatric Diabetes Therapeutic Sales Volume (K Units) by Application (2020-2031)
 Figure 42. Europe Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Germany Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 44. France Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 45. U.K. Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 46. Italy Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 47. Russia Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Pediatric Diabetes Therapeutic Sales YoY (2020-2031) & (K Units)
 Figure 49. Asia-Pacific Pediatric Diabetes Therapeutic Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Top 8 Manufacturers Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) in 2024
 Figure 51. Asia-Pacific Pediatric Diabetes Therapeutic Sales Volume (K Units) by Type (2020- 2031)
 Figure 52. Asia-Pacific Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 53. Asia-Pacific Pediatric Diabetes Therapeutic Sales Volume (K Units) by Application (2020-2031)
 Figure 54. Asia-Pacific Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Indonesia Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 56. Japan Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 57. South Korea Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 58. China Taiwan Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 59. India Pediatric Diabetes Therapeutic Revenue (2020-2031) & (US$ Million)
 Figure 60. Central and South America Pediatric Diabetes Therapeutic Sales YoY (2020-2031) & (K Units)
 Figure 61. Central and South America Pediatric Diabetes Therapeutic Revenue YoY (2020-2031) & (US$ Million)
 Figure 62. Central and South America Top 5 Manufacturers Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) in 2024
 Figure 63. Central and South America Pediatric Diabetes Therapeutic Sales Volume (K Units) by Type (2021-2031)
 Figure 64. Central and South America Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Central and South America Pediatric Diabetes Therapeutic Sales Volume (K Units) by Application (2020-2031)
 Figure 66. Central and South America Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 67. Brazil Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 68. Argentina Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 69. Middle East, and Africa Pediatric Diabetes Therapeutic Sales YoY (2020-2031) & (K Units)
 Figure 70. Middle East and Africa Pediatric Diabetes Therapeutic Revenue YoY (2020-2031) & (US$ Million)
 Figure 71. Middle East and Africa Top 5 Manufacturers Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) in 2024
 Figure 72. Middle East and Africa Pediatric Diabetes Therapeutic Sales Volume (K Units) by Type (2021-2031)
 Figure 73. South America Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 74. Middle East and Africa Pediatric Diabetes Therapeutic Sales Volume (K Units) by Application (2020-2031)
 Figure 75. Middle East and Africa Pediatric Diabetes Therapeutic Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 76. GCC Countries Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 77. Turkey Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 78. Egypt Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 79. South Africa Pediatric Diabetes Therapeutic Revenue (2020-2025) & (US$ Million)
 Figure 80. Pediatric Diabetes Therapeutic Industry Chain Mapping
 Figure 81. Regional Pediatric Diabetes Therapeutic Manufacturing Base Distribution (%)
 Figure 82. Global Pediatric Diabetes Therapeutic Production Market Share by Region (2020-2031)
 Figure 83. Pediatric Diabetes Therapeutic Production Process
 Figure 84. Regional Pediatric Diabetes Therapeutic Production Cost Structure
 Figure 85. Channels of Distribution (Direct Vs Distribution)
 Figure 86. Bottom-up and Top-down Approaches for This Report
 Figure 87. Data Triangulation
 Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Diabetes Mellitus Treatment Market Insights Forecast to 2030
Diabetes Treatment Device Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Type 2 Diabetes Mellitus Treatment Market Research Report 2024
Global Type 1 Diabetes Treatment Market Insights Forecast to 2030
Global Type 2 Diabetes Medicines Market Research Report 2024
Diabetes Drug Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Type 2 Diabetes Medications Market Research Report 2024
Global Diabetes Management Equipment Market Research Report 2024
Global Diabetes Drugs Sales Market Report Competitive Analysis and Regional Opportunities 2025 2031
Global Oral Antidiabetic OAD Treatment Market Research Report 2024
Diabetes Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Diabetes Pump Therapy Market Research Report 2024
Global Diabetes Therapeutics and Diagnostics Market Insights Forecast to 2030
Global Disposable Diabetes Devices Market Research Report 2024
Type 2 Diabetes Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Diabetic Foot Ulcer Therapeutics Market Research Report 2024
Global Needle Free Diabetes Care Market Research Report 2024
Global Diabetic Foot Ulcer Therapeutic Market Research Report 2024
Injectable Drugs For Type 2 Diabete Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oral Anti diabetes Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions